Insulin Glargine vs Detemir
Insulin glargine and insulin detemir are both long-acting basal insulin analogs designed to provide steady-state insulin coverage over 24 hours. However, they achieve prolonged action through fundamentally different biophysical mechanisms: glargine relies on isoelectric precipitation at physiological pH, while detemir leverages fatty acid-mediated albumin binding. These differences produce distinct pharmacokinetic profiles, variability characteristics, and clinical trade-offs.
Chemical Identity
Section titled “Chemical Identity”Insulin Glargine
Section titled “Insulin Glargine”Insulin glargine is a recombinant human insulin analog with two modifications: substitution of asparagine with glycine at position A21 of the A-chain, and addition of two arginine residues at the C-terminus of the B-chain (B31-B32). These modifications shift the isoelectric point (pI) from pH 5.4 (native insulin) to approximately 6.7, which is close to physiological pH (7.4). Molecular weight: 6063 Da. Marketed as Lantus, Toujeo (U-300), and Semglee (biosimilar).
Insulin Detemir
Section titled “Insulin Detemir”Insulin detemir is a recombinant human insulin analog with threonine substituted for threonine at B30 (deletion of B30-Threonine), and a C14 fatty myristic acid chain acylated to lysine at B29. This fatty acid chain enables non-covalent binding to albumin in the subcutaneous tissue and bloodstream, creating a circulating reservoir. Molecular weight: 5917 Da (without fatty acid). Marketed as Levemir.
Mechanism of Action
Section titled “Mechanism of Action”Glargine: Isoelectric Precipitation
Section titled “Glargine: Isoelectric Precipitation”Insulin glargine is formulated as a clear acidic solution (pH 4.0) containing zinc. Upon subcutaneous injection, the neutral pH of interstitial fluid (pH 7.4) causes the glargine molecules to reach their isoelectric point, where they aggregate into amorphous microprecipitates. These precipitates slowly dissolve, releasing insulin monomers into circulation over approximately 24 hours.
The mechanism involves:
- Acidic formulation: pH 4.0 keeps glargine soluble as monomers/dimers
- Neutralization: Subcutaneous pH (7.4) triggers precipitation
- Slow dissolution: Microprecipitates gradually release monomers
- Zinc co-formulation: Zinc hexamers further slow dissolution
- Continuous absorption: Near-zero-order kinetics over 20-24 hours
Detemir: Albumin Binding
Section titled “Detemir: Albumin Binding”Insulin detemir achieves prolonged action through two albumin-binding mechanisms:
- Subcutaneous depot: After injection, detemir molecules bind albumin in the subcutaneous tissue, forming a circulating reservoir
- Systemic albumin binding: Once in circulation, detemir binds albumin at position 1 and 2 binding sites, with approximately 98-99% protein-bound
The fatty myristic acid chain inserts into hydrophobic pockets of albumin, particularly Sudlow’s site 2. This binding is reversible, creating a dynamic equilibrium between bound and free insulin. Detemir also self-associates into dihexamers in the presence of zinc, further slowing initial absorption.
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Insulin Glargine | Insulin Detemir |
|---|---|---|
| Onset of action | 1-2 hours | 1-2 hours |
| Peak | Peakless (near zero-order) | Mild peak at 6-8 hours |
| Duration | ~24 hours (U-100); ~30 hrs (U-300) | 12-24 hours (dose-dependent) |
| Time to steady state | 2-4 days | 2-3 days |
| Bioavailability | ~100% (relative to IV) | ~80% (albumin sequestration reduces bioavailability) |
| Variability (CV%) | 20-30% | 20-30% |
| Protein binding | Minimal (< 1%) | 98-99% |
Duration Differences
Section titled “Duration Differences”A critical pharmacokinetic distinction is duration of action relative to dose:
- Glargine U-100: Duration is relatively fixed at ~24 hours regardless of dose, as the isoelectric precipitation mechanism creates a consistent depot
- Glargine U-300 (Toujeo): Higher concentration creates a smaller subcutaneous depot volume, extending duration to ~30 hours with flatter profile
- Detemir: Duration is dose-dependent — at higher doses (>0.5 U/kg), duration extends to ~24 hours; at lower doses, it may be 12-16 hours, potentially requiring twice-daily dosing
Pharmacodynamic Comparison
Section titled “Pharmacodynamic Comparison”| Parameter | Insulin Glargine | Insulin Detemir |
|---|---|---|
| Glucose clamp duration | 24-26 hours | 12-24 hours (dose-dependent) |
| Insulin sensitivity | Equivalent to NPH | 20% less weight gain vs NPH |
| FFA suppression | Normal | Enhanced (beyond glucose lowering) |
| Glucagon suppression | Normal | Enhanced |
| Hypoglycemia (nocturnal) | Lower vs NPH | Lower vs NPH |
| Weight gain | Similar to NPH | 50% less vs NPH |
The Detemir Weight Advantage
Section titled “The Detemir Weight Advantage”Detemir produces significantly less weight gain than other basal insulins. This is attributed to its albumin-binding pharmacokinetics and direct CNS effects:
- Hypothalamic access: Detemir’s fatty acid chain may facilitate transport across the blood-brain barrier
- Appetite suppression: Animal studies show detemir reduces food intake via hypothalamic mechanisms
- Peripheral effects: Reduced lipogenesis and enhanced lipolysis suppression compared to other basal insulins
- Clinical significance: 1-2 kg less weight gain over 6-12 months vs glargine in head-to-head trials
Dosing Flexibility
Section titled “Dosing Flexibility”Glargine
Section titled “Glargine”- Once-daily dosing (same time each day)
- No dose splitting
- Toujeo (U-300) allows higher concentrations for patients needing >80 U/day
- Can be mixed with rapid-acting insulin in the same syringe (but not in pump)
- No dose adjustment for renal/hepatic impairment (though caution warranted)
Detemir
Section titled “Detemir”- Once-daily at doses >0.5 U/kg
- Twice-daily dosing may be needed at lower doses
- More flexible timing — can be adjusted ±2 hours without significant impact
- Can be mixed with rapid-acting insulin
- Dose reduction recommended in renal impairment (reduced clearance)
Hypoglycemia Profile
Section titled “Hypoglycemia Profile”| Type | Glargine | Detemir |
|---|---|---|
| Nocturnal hypoglycemia | Reduced vs NPH | Reduced vs NPH |
| Severe hypoglycemia | Similar to NPH | Similar to NPH |
| Asymptomatic hypoglycemia | Similar | Similar |
| Hypoglycemia unawareness | Risk with tight control | Risk with tight control |
Both analogs reduce nocturnal hypoglycemia compared to NPH insulin, but neither eliminates it entirely. The flatter profiles of both agents contribute to reduced hypoglycemic risk, though individual variability remains a clinical concern.
Renal and Hepatic Considerations
Section titled “Renal and Hepatic Considerations”Renal Impairment
Section titled “Renal Impairment”- Glargine: Active metabolites M1 and M2 are renally cleared; accumulation possible in severe CKD
- Detemir: Primarily hepatic metabolism; less renal accumulation, but dose reduction still recommended in GFR <50 mL/min
Hepatic Impairment
Section titled “Hepatic Impairment”- Glargine: Reduced insulin clearance; lower doses may be needed
- Detemir: Hepatic albumin synthesis may be reduced, affecting protein binding and free insulin levels
Clinical Evidence
Section titled “Clinical Evidence”Head-to-Head Trials
Section titled “Head-to-Head Trials”- ORIGIN Trial (2012): Glargine vs standard therapy in 12,537 patients with cardiovascular risk factors — no significant difference in CV outcomes; glargine reduced progression to diabetes
- SWITCH Trial (2017): Detemir vs glargine in type 1 diabetes — similar HbA1c, lower nocturnal hypoglycemia with detemir
- Pooled Analysis: Detemir associated with 0.5-1.0 kg less weight gain than glargine across multiple trials
Type 1 vs Type 2 Diabetes
Section titled “Type 1 vs Type 2 Diabetes”- Type 1: Both agents provide equivalent glycemic control; detemir may have slight advantage in weight neutrality
- Type 2: Glargine U-300 (Toujeo) shows lower hypoglycemia vs glargine U-100; detemir shows weight advantage
Safety and Immunogenicity
Section titled “Safety and Immunogenicity”Glargine
Section titled “Glargine”- Anti-insulin antibody formation: ~2-3% of patients
- Cross-reactivity with endogenous insulin: minimal
- Local lipodystrophy: uncommon with proper rotation
- Theoretical concern: higher IGF-1 receptor affinity (clinically insignificant)
Detemir
Section titled “Detemir”- Anti-insulin antibody formation: ~1-2% of patients
- No significant cross-reactivity
- Local reactions: uncommon
- No IGF-1 receptor affinity concerns
When to Choose Which
Section titled “When to Choose Which”Glargine may be preferred when:
- Strict once-daily dosing with minimal variability is desired
- U-300 concentration needed for high-dose requirements (>80 U/day)
- Pump therapy transition (compatible with some pump systems)
- Cost considerations (biosimilar Semglee available)
- Fixed dosing schedule is acceptable
Detemir may be preferred when:
- Weight gain is a significant concern
- Flexible dosing timing is important
- Twice-daily dosing is acceptable for better control
- Renal impairment is present (hepatic clearance advantage)
- Hypothalamic appetite effects are desired
References
Section titled “References”- Heinemann L, et al. “Insulin glargine (HOE 901): a new insulin analogue.” Diabetes Obes Metab 2000;2:131-137.
- Plank J, et al. “A comparison of insulin analogues NPH insulin, insulin glargine and insulin detemir.” Diabetes Obes Metab 2005;7:642-649.
- Russell-Jones D, et al. “Less nocturnal hypoglycaemia with insulin detemir compared with NPH insulin.” Diabetologia 2004;47:1822-1828.
- Home PD, et al. “Insulin detemir: pharmacokinetics of a new-generation basal insulin.” Diabetes Obes Metab 2007;9:207-215.
- Owens DR, et al. “Insulin glargine: a review of its clinical efficacy and pharmacokinetics.” Clin Drug Investig 2001;21:1-22.